RNA specialist Wave Life Sciences has been told by Takeda that the Japanese drugmaker is to bring to an end the last facet of ...

A life sciences company has sold off part of its business that includes a Morrisville facility with hundreds of workers.

Fintel reports that on October 16, 2024, Raymond James upgraded their outlook for Wave Life Sciences (NasdaqGM:WVE) from ...

Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The ...

Wave Life Sciences Ltd. said it achieved so-called proof-of-mechanism in a single-dose trial of its potential treatment for a genetic disorder that causes lung and liver diseases. Its stock surged as ...

While RNA-medicine developer Wave Life Sciences Ltd. brought in a clinical data win, it also got knocked back a step as a major collaborator will go its separate way. That didn’t stop Wave’s stock ...

Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of ...

Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE ...

ATNF announces an acquisition to pivot into online gaming. Investors should tread with caution while investing in 180 Life ...

An experimental therapy designed to change a single letter of short-lived mRNA molecules has corrected a genetic mutation ...

Science emphasizes the science necessary to understand those aspects of the coupled Sun-Earth system that affect life and ...

Wave Life Sciences is a clinical-stage biotechnology company based in Cambridge, MA, dedicated to unlocking the potential of RNA medicines to transform human health. With a robust pipeline focused on ...